Compare SENS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SENS | PROF |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.2M | 243.2M |
| IPO Year | 2014 | 2017 |
| Metric | SENS | PROF |
|---|---|---|
| Price | $5.94 | $7.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $18.38 | $12.00 |
| AVG Volume (30 Days) | ★ 995.5K | 81.9K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $16,389,000.00 | $16,098,000.00 |
| Revenue This Year | $74.15 | $92.40 |
| Revenue Next Year | $58.60 | $64.10 |
| P/E Ratio | ★ N/A | $36.26 |
| Revenue Growth | 19.85 | ★ 50.73 |
| 52 Week Low | $0.41 | $3.92 |
| 52 Week High | $8.75 | $8.95 |
| Indicator | SENS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 58.80 |
| Support Level | $5.41 | $7.00 |
| Resistance Level | $8.55 | $7.97 |
| Average True Range (ATR) | 0.46 | 0.46 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 41.92 | 56.48 |
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.